Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, associate professor of lymphoma and myeloma and director, Translational and Laboratory Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
Transcript
Tell us about your study on the mechanisms of anti-CD19 CAR T-cell therapy, Yescarta (axicabtagene ciloleucel [axi-cel]), for diffuse large B-cell lymphoma.
Cellular therapy, in general, has been a breakthrough in cancer therapy, but in the space of relapsed/ refractory large B-cell lymphoma, CD19 CAR T cells have dramatically improved patient outcomes. But approximately 50% of patients will not have a durable response to CAR T cells, and treatment-associated adverse events continue to be a problem in the clinic to manage.
There are several potential factors that can contribute to these problems. One is with the CAR T-cell product itself, [the second] would be patient-intrinsic characteristics, and [the third] would be tumor-intrinsic characteristics. And so here we're primarily focused on characteristics and heterogeneity of the CD19 CAR T-cell products that are being infused into the patient.
What were the molecular/cellular features of patients who better responded axi-cel?
So the answer to that is 2-fold. Really what we identified were features that were more desirable and other features that were less desirable. And it’s really the mixture of desirable and undesirable phenotypes within the final product that were associated with outcome. So when we were looking for associations with clinical response measured by PET CT at the 3-month follow up, what we found was a significant enrichment of central memory CD8 T-cell phenotypes within patients that had a complete response and less of those within the infusion products of patients that have partial response or progressive disease.
We also looked at other measures of response using circulating tumor [CT] DNA to measure molecular response within the first week following infusion, which was itself associated with clinical response measured by PET CT. But when we looked with its characteristics associated with molecular response by CT DNA, we found a very strong enrichment for exhausted CD8 T cells among those patients that had a poor molecular response.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More